Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT

帕洛诺塞隆 医学 恶心 呕吐 消炎药 地塞米松 临床终点 化疗 随机对照试验 胃肠病学 麻醉 内科学 止吐药
作者
Huaqiang Zhou,Yuanyuan Zhao,Mingjun Zhang,Jun Yao,Shuang Leng,Xiu-Min Li,Lin Li,J Chen,Songnan Zhang,Xia Qin,Zhiquan Qin,Tienan Yi,Ruoyu Wang,Xiang Li,Yan Yu,Zhenghua Wang,Qinhong Zheng,Jiazhuan Mei,Aimin Zang,Na Li
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (9): 1123-1136 被引量:10
标识
DOI:10.1200/jco-24-01308
摘要

PURPOSE Mixed formulation of fosrolapitant and palonosetron (PALO), HR20013, is a novel fixed-dose intravenous antiemetic combination that could simultaneously antagonize neurokinin-1 and 5-hydroxytryptamine-3 receptors. This study was designed to evaluate the efficacy and safety of HR20013 plus dexamethasone (DEX) versus fosaprepitant (FAPR) plus PALO + DEX for preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). METHODS This is a noninferiority study. Chemotherapy-naïve patients were randomly assigned 1:1 to receive HR20013 (day 1) or FAPR + PALO (day 1) before each cycle of cisplatin-based HEC (two cycles in total), together with oral DEX (day 1-4). The primary end point was overall (0-120 hours) complete response (CR; no vomiting/no rescue therapy) rate in cycle 1. The key secondary end point was CR rate at the beyond delayed phase (120-168 hours) in cycle 1. RESULTS Three hundred seventy-three patients were enrolled to receive HR20013 + DEX and 377 to FAPR + PALO + DEX. The overall CR rate in cycle 1 was 77.7% for HR20013 + DEX and 78.2% for FAPR + PALO + DEX (difference = –0.9% [95% CI, –6.7 to 5.0]; one-sided P < .01), demonstrating that HR20013 + DEX was noninferior to FAPR + PALO + DEX. The superiority of HR20013 + DEX over FAPR + PALO + DEX in CR rate at the beyond delayed phase in cycle 1 was not met (90.3% v 86.5%; two-sided P = .11). In cycle 2, HR20013 + DEX showed greater proportions of patients reporting no impact on daily life at the delayed (24-120 hours) and beyond delayed phases compared with FAPR + PALO + DEX. The incidences of treatment-related adverse events were 35.7% during cycle 1 and 42.1% during entire study for HR20013 + DEX, versus 38.2% and 44.0% for FAPR + PALO + DEX. CONCLUSION HR20013 + DEX was noninferior to FAPR + PALO + DEX for preventing HEC-CINV and well tolerated, with the potential to reduce the impact of CINV on daily life.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
搜集达人的应助被坚强孤容采纳,获得10
刚刚
1秒前
1秒前
Hello的应助被徐XU采纳,获得10
2秒前
七七完成签到 ,获得积分10
2秒前
rongjian完成签到 ,获得积分10
3秒前
人间慈悲的应助被辛勤的西牛采纳,获得10
3秒前
4秒前
4秒前
张二发布了新的文献求助10
6秒前
6秒前
surge发布了新的文献求助10
6秒前
7秒前
小情绪发布了新的文献求助10
7秒前
现代雪珍完成签到,获得积分10
7秒前
等待思远发布了新的文献求助10
8秒前
风中的香寒完成签到 ,获得积分10
8秒前
HIlda完成签到,获得积分10
9秒前
安详靖柏完成签到,获得积分10
9秒前
Boubou发布了新的文献求助10
10秒前
ing完成签到 ,获得积分10
10秒前
周周发布了新的文献求助200
11秒前
青街向晚完成签到,获得积分10
11秒前
surge完成签到,获得积分10
11秒前
maguodrgon发布了新的文献求助30
12秒前
哈哈客完成签到,获得积分10
12秒前
mogu完成签到 ,获得积分10
13秒前
仲乔妹完成签到,获得积分0
13秒前
15秒前
等待思远完成签到,获得积分10
15秒前
15秒前
16秒前
Eric完成签到,获得积分20
16秒前
kid1412完成签到,获得积分10
18秒前
Power_Liu完成签到,获得积分10
18秒前
18秒前
852的应助被jls采纳,获得10
18秒前
留的白完成签到,获得积分10
18秒前
篮球完成签到,获得积分10
19秒前
徐徐发布了新的文献求助10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186734
求助须知:如何正确求助?哪些是违规求助? 9575007
关于积分的说明 21839114
捐赠科研通 7784289
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559206
邀请新用户注册赠送积分活动 2481611